As an established provider of in vitro and in vivo models in oncology and other therapeutic fields (angiogenesis, metastasis, diabetes, CNS, etc.), CELLVAX, a French SME founded in 2001, has consolidated skills in animal modelling for preclinical R&D. In the oncology field CELLVAX offers access to subcutaneous and orthotopic animal xenografts. CELLVAX also offers a range of pre-clinical screenings suitable for the biotechnology and pharmaceutical markets, including toxicology, biodistribution, pharmacokinetic studies, etc.

The products and services that ANIMASCOPE and CELLVAX provide complement each other, and so the two companies have signed a collaboration agreement to foster the development and promotion of added value services for disease animal models in therapeutic areas where there are unmet medical needs, including oncology and other severe human diseases.

This synergistic collaboration between our two companies will provide more complete and efficient services to our customers and allow the drug development process to be speeded up.